The H5N1 avian influenza virus (AIV) has widely spread in Asia, Europe and Africa, making a large amount of economic loss. Recently, our research group has screened a common neutralizing monoclonal antibody named 8H5, which can neutralize almost all H5 subtype AIV ever isolated so far. Obviously, this monoclonal antibody would benefit for research and development of the universal AIV vaccine and design of the drug against H5N1 AIV in high mutation rate. In this study, the homology modeling was applied to generate the 3D structure of 8H5 Fab fragment, and "canonical structure" method was used to define the specified loop conformation of CDR regions. The model was subjected to energy minimization in cvff force field with Discovery module in Insight II program. The resulting model has correct stereochemistry as gauged from the Ramachandran plot calculation and good 3D-structure compatibility as assessed by interaction energy analysis, solvent accessible surface (SAS) analysis, and Profiles-3D approach. Furthermore, the 8H5 Fab model was subjected to docking with three H5 subtype hemagglutinin (HA) structures deposited in PDB (ID No: 1jsm, 2ibx and 2fk0) respectively. The result indicates that the three docked complexes share a common binding interface, but differ in binding angle related with HA structure similarity between viral subtypes. In the light of the three HA interfaces with structural homology analysis, the common neutralizing epitope on HA recognized by 8H5 consists of 9 incontinuous amino acid residues: 1jsm sequence) . The primary purpose of the present work is to provide some insight into structure and binding details of a common neutralizing epitope of H5N1 AIV, thereby aiding in the structure-based design of universal AIV vaccines and anti-virus therapeutic drugs.
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Since late 2003, H5N1 avian influenza virus (AIV) has widely spread all over the world, not only resulting in mass poultry death, but also leading to high mortality in human patients. Hemagglutinin (HA), the major surface protein of AIV, not only mediates viral attachment and entry into the host cell by binding to sialic acid receptors, but also is responsible for protective humoral immunity by neutralizing antibody. However, the high mutation ratio of HA makes it very difficult to control AIV. Recently we have constructed an antibody panel that contained 388 antibodies possessing H5 hemagglutinin inhibited (HI) activity. In this panel, one antibody 8H5 can strongly neutralize all of the 46 viruses isolated from different clades, locations and hosts [1] . The research on the structure of this common neutralizing antibody may contribute to a breakthrough in seeking methods to overcome the high mutation of H5N1.
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Because antibody has an intrinsic nature with conserved amino acid sequence and typical configuration in 3D structure, the structure can be modeled by some structural templates from Brookhaven PDB where a large number of X-ray resolved antibody structures deposit [2, 3] . The homology modeling method has been widely used to search for the epitopes of antigen and to improve the binding affinity. Frequently 5 of the 6 complementarity-determining regions (CDRs) (all except H3) of antibody fall into one of between 2 and 6 structural classes, referred to as canonical classes [3, 4] . Based on the determinants of the canonical structures, the most accurate method for building the model of antibody can be developed [5] . Here we will describe the structure modeling of 8H5 using the canonical structure method and the docking pattern between 8H5 and three HAs deposited in PDB. The docking results can shed light on the common neutralizing epitope of H5, thus providing invaluable information for the development of the potential vaccine, design of antiviral drug and research on the broad-spectrum therapeutic antibody.
Materials and methods
Antibody sequence preparation and antigen structure refinement
The monoclonal antibody 8H5 was raised in our lab, and the gene of variable regions was cloned from the hybrid plasmoma cell and verified with sequencing by BoYa Co. in Shanghai [1] . The primary amino acid sequence of the variable regions is listed below: Variable region of light chain, EIVLTQSPAIMSASLGEKVTMSCRASSSVNF-VYWYQQRSDASPKLLIYYSSNLAPGVPPRFSGSGS-GNSYSLTISGLEGEDAATYYCQHFTSSPYTFGGGT-KLEIKRLE; Variable region of heavy chain, QVQLQQ-SGAELMKPGASVKISCKATGYTFSNYWIEWIKQR-PGHGLEWIGEILPGSDRTNYNGKFKGKATFTADT-SSNTAHMQLSSLTSEDSAVYYCANRYDGYYFGL-DYWGQGTSVTVSS.
There were 3 X-ray resolved HA antigen structures depositing in PDB. The PDB IDs were as follows: 1jsm (Virus strain: A/DUCK/SINGAPORE/3/97, Host: Bird), 2fk0 (Virus strain: A/VIETNAM/1203/2004, Host: Human) and 2bix (Virus strain: VN1194, Host: Human) [6] [7] [8] . The structure of 1jsm was refined in Insight II package (Accelrys Company) before docking with the antibody. Because the other 2 structures were deposited as the trimers, the monomers were unmerged and then subjected to refinement before docking.
Chothia numbering of antibody sequence and canonical structure analysis
According to Chothia numbering scheme, the amino acid insertion and deletion site in antibody were located in residues L31, L95, L106, H31, H52, H82 and H100 [2] . For the variable domain in light chain (VL), the conserved residue cysteine was always located in residues 23 and 88 which were 1 residue ahead of the start point of CDR-L1 and CDR-L3 respectively. The residue after CDR-L1, which ranged from residue 24 to 33, was always Trp and the residues after CDR-L3, which ranged from residue 89 to 97, were always Phe-Gly. CDR-L2, which ranged from residue 50 to 56, always started sixteen residues after the end of L1. The residues before CDR-L2 generally were Ile-Tyr. For the variable domain in heavy chain (VH), the conserved residue cysteine was always located in residues 22 and 92, which were 4 and 3 residues ahead of the start point of CDR-H1 and CDR-H3, respectively. The residue after CDR-H1, which ranged from residue 26 to 32, was always Trp and the residues after CDR-H3, which ranged from residue 95 to 102, were always Trp-Gly. CDR-H2, which ranged from residue 52 to 56, always started 15th residues after the end of H1. The residues before CDR-H2 typically were Leu-Glu-Trp-Ile-Gly and the residues after CDR-H2 were Lys/Arg-Leu/Ile/Val/Phe/Thr/Ala-Thr/Ser/Ile/Ala. Inspite of the high sequence variability in CDRs, five of them (all except CDR-H3) can assume just a small repertoire of main-chain conformation, called canonical structures, and each of the 5 CDRs fell into 1 of between 2 and 6 canonical structure classes. The conformations for canonical structures were determined by the length of the loops and by the presence of key residues at specific positions in the antibody sequence (either within the loops or in the framework regions) [5] .
Molecular modeling of L and H chains
In the Homology module of Insight II software package, L and H sequences were aligned with the sequences from PDB using FASTA method [9, 10] . The protein structures with >50% homology to the targets were selected as templates. The conserved residue coordinates in framework were first assigned. For the canonical structures, the coordinates from PDB with the same canonical classes as targets were adopted and assigned to the L or H sequences. For the CDR-H3, the sequence was also sent to PDB to seek the best loop coordinate, and the
